Log In Sign up
The largest database of trusted experimental protocols

Tgf β1 type 2 receptor shrna

Manufactured by Santa Cruz Biotechnology
Visit Supplier

The TGF-β1 type II receptor shRNA is a laboratory tool designed to suppress the expression of the TGF-β1 type II receptor gene. This receptor is a key component in the TGF-β signaling pathway. The shRNA (short hairpin RNA) molecule is engineered to target and degrade the mRNA transcripts of the TGF-β1 type II receptor, effectively reducing its expression in cell culture or experimental models.

Automatically generated - may contain errors

Lab products found in correlation

Recombinant human opn and tgf β1 proteins, by R&D Systems (2 mentions) αvβ3 integrin and cd44 abs, by Santa Cruz Biotechnology (2 mentions) Sb431542 a tgf β1 type 1 receptor inhibitor, by Merck Group (2 mentions) Mzf1 sirna, by Thermo Fisher Scientific (2 mentions)

Spelling variants of this product

TGF-β1 (146 citations)

2 protocols using tgf β1 type 2 receptor shrna

1

Exploring OPN-R3 Aptamer Interactions

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
The pharmacologic properties and sequences of OPN-R3 aptamer (APT) and mutant aptamer (MuAPT) have been previously published.28 (link)Recombinant human OPN and TGF-β1 proteins (R&D Systems, Minneapolis, MN); αvβ3 integrin and CD44 Abs (Santa Cruz Biotechnology, Santa Cruz, CA); Arg-Gly-Asp (RGD), Arg-Gly-Glu (RGE) (Sigma-Aldrich, St Louis, MO); SB431542 a TGF- β1 type I receptor inhibitor (EMD Millipore, Billerica, MA); TGF-β1 type II receptor shRNA (Santa Cruz Biotechnology); MZF1 siRNA (Life Technologies, Carlsbad, CA); and Control siRNA81 (link): UAAGGCUAUGAAGAGAUAC were all obtained.
Weber C.E., Kothari A.N., Wai P.Y., Li N.Y., Driver J., Zapf M.A., Franzen C.A., Gupta G.N., Osipo C., Zlobin A., Syn W.K., Zhang J., Kuo P.C, & Mi Z. (2014). Osteopontin Mediates an MZF1-TGF-β1-Dependent Transformation of Mesenchymal Stem Cells into Cancer Associated Fibroblasts in Breast Cancer. Oncogene, 34(37), 4821-4833.
+ Open protocol
+ Expand
2

Exploring OPN-R3 Aptamer Interactions

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
The pharmacologic properties and sequences of OPN-R3 aptamer (APT) and mutant aptamer (MuAPT) have been previously published.28 (link)Recombinant human OPN and TGF-β1 proteins (R&D Systems, Minneapolis, MN); αvβ3 integrin and CD44 Abs (Santa Cruz Biotechnology, Santa Cruz, CA); Arg-Gly-Asp (RGD), Arg-Gly-Glu (RGE) (Sigma-Aldrich, St Louis, MO); SB431542 a TGF- β1 type I receptor inhibitor (EMD Millipore, Billerica, MA); TGF-β1 type II receptor shRNA (Santa Cruz Biotechnology); MZF1 siRNA (Life Technologies, Carlsbad, CA); and Control siRNA81 (link): UAAGGCUAUGAAGAGAUAC were all obtained.
Weber C.E., Kothari A.N., Wai P.Y., Li N.Y., Driver J., Zapf M.A., Franzen C.A., Gupta G.N., Osipo C., Zlobin A., Syn W.K., Zhang J., Kuo P.C, & Mi Z. (2014). Osteopontin Mediates an MZF1-TGF-β1-Dependent Transformation of Mesenchymal Stem Cells into Cancer Associated Fibroblasts in Breast Cancer. Oncogene, 34(37), 4821-4833.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!